(RS)-(E)-3-(2,6-dichloro-4-{4-[3-(2,2-dimethylpropyl-1-ethoxy)-2-methyloxyphenyl]thiazol-2-ylcarbamoyl}phenyl)-2-methylacrylic acid | 1110767-41-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (RS)-(E)-3-(2,6-dichloro-4-{4-[3-(2,2-dimethylpropyl-1-ethoxy)-2-methyloxyphenyl]thiazol-2-ylcarbamoyl}phenyl)-2-methylacrylic acid
• 英文别名: (E)-3-[2,6-dichloro-4-[[4-[3-(1-ethoxy-2,2-dimethylpropyl)-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
• CAS: 1110767-41-3
• 化学式: C₂₈H₃₀Cl₂N₂O₅S
• 分子量: 577.529
• InChiKey: NUGCFHQUYHXPIC-RVDMUPIBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  38
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR
  申请人：Shionogi & Co., Ltd.

  公开号：US20130217885A1

  公开（公告）日：2013-08-22

  An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided. Disclosed is a pharmaceutical composition containing, as an active ingredient, an optically active compound represented by the formula: wherein, R 1 is a halogen atom or C1-C8 alkyloxy; R 2 is C1-C8 alkyl; R 3 is C1-C8 alkyl; R 4 and R 5 are each independently a fluorine atom or chlorine atom; R 6 is C1-C3 alkyl or C1-C3 alkyloxy; * indicates that a carbon atom marked with an asterisk is an asymmetric carbon, a pharmaceutically acceptable salt thereof, or a solvate thereof.

  创造了一种具有血小板生成素受体激动剂活性的光学活性4-苯基噻唑衍生物和含有该化合物作为活性成分的制药组合物，并提供了一种可以口服的调节血小板生成的药物。本发明揭示了一种制药组合物，其含有以下式子所表示的光学活性化合物作为活性成分：其中，R1是卤素原子或C1-C8烷氧基；R2是C1-C8烷基；R3是C1-C8烷基；R4和R5分别独立地是氟原子或氯原子；R6是C1-C3烷基或C1-C3烷氧基；*表示带星号的碳原子是不对称碳原子，其药学上可接受的盐或其溶剂化物。
• Preparation for Improving Solubility of Poorly Soluble Drug
  申请人：Sakuma Satoshi

  公开号：US20130203723A1

  公开（公告）日：2013-08-08

  The present invention relates to solubility improving preparation for enhancing the oral absorption of a poorly soluble drug, which is comprising (A) and (B); (A) a granulated substance which comprises (i) a poorly soluble drug having an acidic group in the molecule, (ii) an alkaline agent, (iii) a surfactant, and this granulated substance dose not substantially contain a disintegrator, (B) a disintegrator existing only in the external of the granulated substance.
• US8530668B2
  申请人：——

  公开号：US8530668B2

  公开（公告）日：2013-09-10
• US8889722B2
  申请人：——

  公开号：US8889722B2

  公开（公告）日：2014-11-18
• US9427402B2
  申请人：——

  公开号：US9427402B2

  公开（公告）日：2016-08-30